$40.47
-1.03%
N/A-$0.42
Healthcare
Biotechnology
NASDAQ
활발히 거래 중
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of ...
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of ...
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | MCLAUGHLIN KEVIN F | director | Common Stock | A | 7,000 | $13.05 |
| Aug 12, 2026 | MCLAUGHLIN KEVIN F | director | Common Stock | D | 7,000 | $44.53 |
| Aug 12, 2026 | MCLAUGHLIN KEVIN F | director | Stock Option (Right to Buy) | A | 7,000 | $13.05 |
| Aug 3, 2026 | Halpin Michael | officer: Chief Operating Officer | Common Stock | A | 10,000 | $16.66 |
| Aug 3, 2026 | Halpin Michael | officer: Chief Operating Officer | Stock Option (Right to Buy) | A | 10,000 | $16.66 |
매수/매도 주식 수와 종가 추세(공통 일간 가격 소스)
X축: 주식 수, 총 주식 수 내림차순
X축: 건수, A+D 건수 내림차순
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 | 금액 |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | MCLAUGHLIN KEVIN F | director | Common Stock | A | 7,000 | $13.05 | $91,350.00 |
| Aug 12, 2026 | MCLAUGHLIN KEVIN F | director | Common Stock | D | 7,000 | $44.53 | $311,710.00 |
| Aug 12, 2026 | MCLAUGHLIN KEVIN F | director | Stock Option (Right to Buy) | A | 7,000 | $13.05 | $91,350.00 |
| Aug 3, 2026 | Halpin Michael | officer: Chief Operating Officer | Common Stock | A | 10,000 | $16.66 | $166,600.00 |
| Aug 3, 2026 | Halpin Michael | officer: Chief Operating Officer | Stock Option (Right to Buy) | A | 10,000 | $16.66 | $166,600.00 |
| Aug 3, 2026 | Halpin Michael | officer: Chief Operating Officer | Common Stock | D | 10,000 | $46.84 | $468,400.00 |
| Jul 30, 2026 | SIEGAL JONATHAN | officer: Principal Accounting Officer | Stock Option (Right to Buy) | A | 2,500 | $29.82 | $74,550.00 |
| Jul 30, 2026 | SIEGAL JONATHAN | officer: Principal Accounting Officer | Common Stock | A | 2,500 | $29.82 | $74,550.00 |
| Jul 30, 2026 | SIEGAL JONATHAN | officer: Principal Accounting Officer | Stock Option (Right to Buy) | A | 500 | $29.82 | $14,910.00 |
| Jul 30, 2026 | SIEGAL JONATHAN | officer: Principal Accounting Officer | Stock Option (Right to Buy) | A | 1,500 | $34.90 | $52,350.00 |